Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.

European journal of clinical pharmacology - 1 Aug 2006

Shimizu Mikiko, Uno Tsukasa, Yasui-Furukori Norio, Sugawara Kazunobu, Tateishi Tomonori

Abstract excerpt

OBJECTIVE: Rabeprazole as a proton pump inhibitor (PPI) is mainly reduced to rabeprazole thioether via a nonenzymatic pathway, with minor CYP2C19 and CYP3A4 involvement. The aim of this study was to compare possible effects of clarithromycin and verapamil as inhibitors of CYP3A4 on the pharmacokinetics of rabeprazole among CYP2C19 genotypes. METHODS: A three-way randomized, double-blind, placebo-controlled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clarithromycin

Share to Cytochrome P-450 Enzyme Inhibitors

Share to Half-Life

Share to Metabolic Clearance Rate

Share to Rabeprazole

Share to Verapamil

Source

Identifiers

PMID: 16783561
DOI: 10.1007/s00228-006-0152-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.PMID 16783561Read ↗

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.Semantic proximity Read ↗

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Semantic proximity Read ↗

CYP2C19 genotype and the PPIs--focus on rabeprazole.Semantic proximity Read ↗

Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.Semantic proximity Read ↗

Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.Semantic proximity Read ↗

Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.Semantic proximity Read ↗

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.Semantic proximity Read ↗

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.Semantic proximity Read ↗

Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.Semantic proximity Read ↗

Enantioselective disposition of lansoprazole and rabeprazole in human plasma.Semantic proximity Read ↗

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.